Dr Matthew Glover
Academic and research departments
School of Biosciences, Faculty of Health and Medical Sciences, Department of Clinical and Experimental Medicine, Surrey Health Economics Centre.About
Biography
Matt Glover is a health economist with experience in both academia and consultancy. Following the completion of a BA (Hons) in Economics at the University of Durham and an MSc in Health Economics at University of York, Matt joined the Health Economics Research Group at Brunel University London, first as a Research Assistant, later becoming a Research Fellow. After three years in consultancy, Matt joined the Surrey Health Economics Centre in 2019 in a research focussed role. He was recently awarded a PhD at Brunel University London, reflecting on the role of economic modelling in health technology and research impact assessment.
His role at Surrey is research focussed, working with internal and external colleagues on funded projects. As co-investigator he has held grants funded by Wellcome Trust, NIHR and UKRI. Current projects include economic evaluations alongside clinical trials (REDUCE-2; NIHR HTA) and early modelling of cost-effectiveness (Cortirio brain imaging; NIHR i4i & UKRI.). Recently completed projects include STARQ, considering implications of different care-home staffing and PROTECT-CH, a platform trial in care homes to test prophylactic interventions for COVID-19. He also a Research Adviser for the South East NIHR Research Design Service.
Matt holds a part-time teaching position as Lecturer in Health Economics at Brunel University London and is Programme Director of MSc Health Economics and Health Policy (online).
Areas of specialism
My qualifications
ResearchResearch interests
Matt’s research interests are largely in the methods and applications of health technology assessment, with a focus on decision analytic modelling. He has also been involved in numerous randomised controlled trials assessing the cost-effectiveness of a range of interventions, including health service delivery, in diverse therapeutic areas.
Research interests
Matt’s research interests are largely in the methods and applications of health technology assessment, with a focus on decision analytic modelling. He has also been involved in numerous randomised controlled trials assessing the cost-effectiveness of a range of interventions, including health service delivery, in diverse therapeutic areas.
Publications
South Asians are at high risk of type 2 diabetes (T2D). We assessed whether intensive family-based lifestyle intervention leads to significant weight loss, improved glycaemia and blood pressure in adults at elevated risk for T2D. This cluster randomised controlled trial (iHealth-T2D) was conducted at 120 locations across India, Pakistan, Sri Lanka and the UK. We included 3684 South Asian men and women, aged 40-70 years, without T2D but with raised haemoglobin A1c (HbA1c) and/or waist circumference. Participants were randomly allocated either to the family-based lifestyle intervention or control group by location clusters. Participants in the intervention received 9 visits and 13 telephone contacts by community health workers over 1-year period, and the control group received usual care. Reductions in weight (aim >7% reduction), waist circumference (aim ≥5 cm reduction), blood pressure and HbA1C at 12 months of follow-up were assessed. Our linear mixed-effects regression analysis was based on intention-to-treat principle and adjusted for age, sex and baseline values. There were 1846 participants in the control and 1838 in the intervention group. Between baseline and 12 months, mean weight of participants in the intervention group reduced by 1.8 kg compared with 0.4 kg in the control group (adjusted mean difference -1.10 kg (95% CI -1.70 to -1.06), p
People from South Asia are at increased risk of type 2 diabetes (T2D). There is an urgent need to develop approaches for the prevention of T2D in South Asians that are cost-effective, generalisable and scalable across settings. Compared to usual care, the risk of T2D can be reduced amongst South Asians with central obesity or raised HbA1c, through a 12-month lifestyle modification programme delivered by community health workers. Cluster randomised clinical trial (1:1 allocation to intervention or usual care), carried out in India, Pakistan, Sri Lanka and the UK, with 30 sites per country (120 sites total). Target recruitment 3600 (30 participants per site) with annual follow-up for 3 years. South Asian, men or women, age 40-70 years with (i) central obesity (waist circumference ≥ 100 cm in India and Pakistan; ≥90 cm in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0-6.4% inclusive). known type 1 or 2 diabetes, normal or underweight (body mass index